SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-095433
Filing Date
2024-08-12
Accepted
2024-08-12 16:11:03
Documents
12
Period of Report
2024-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kytx-20240812.htm   iXBRL 8-K 41851
2 EX-99.1 kytx-ex99_1.htm EX-99.1 192816
  Complete submission text file 0000950170-24-095433.txt   363280

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20240812.xsd EX-101.SCH 25978
14 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20240812_htm.xml XML 4932
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

IRS No.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 241196872
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)